Home | Clinical Practice | Vaccine rollout halves infant RSV hospitalisations

Vaccine rollout halves infant RSV hospitalisations

Early data shows the government's $174.5m ”world-leading” free respiratory syncytial virus (RSV) immunisation program for babies and expecting mothers has been a major success.

Please login below to view content or subscribe now.

Membership Login

Get the news delivered straight to your inbox

Receive the top stories in our weekly newsletter Sign up now